SIGN UP TO VIEW THE FULL ARTICLE

Receive a 90-day free trial of Celltelligence and get instant access to our full offering.


EMAIL BLASTS

Curated cell therapy industry news in your inbox multiple times each week

SEARCHABLE LIBRARY

A full archive of cell therapy news, insights, and context

THE MAP

A 24/7 information center that lets you make unique connections

The price for access is $0.00.

Do you have a discount code? Click here to enter your discount code.

Account Information

LEAVE THIS BLANK

By selecting this, I agree to receive emails from celltelligence.com.

Already have an account? Log in here
RETURN TO HOME
$0
Autologous, BCMA, CAR-T, CD19

We’re Back! Holiday Recap Ahead of JPM 2024 (Blast 2/2): Risk of Secondary Hematological Malignancies Included in the Black Box of Carvykti’s US Prescribing Information; FDA Approved Yescarta’s Label Update to Incorporate OS Data; Galapagos Initiates Recruitment of GLPG5301 Trial in ≥3L MM

Here is a brief preview of this blast: Ahead of JPM Week, Celltelligence is publishing a series of 2 blasts with the most important cell therapy-related news items that occurred during the holidays. In this second blast, the following news are covered:

About The Author

The Celltelligence Team

|
Content Leads & Contributors
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.